Carl Zeiss Meditec : Präsentation Telefonkonferenz Quartalsmitteilung Q1 2022/23

Carl Zeiss Meditec Group

3M Results FY 2022/23

Dr. Markus Weber, President and CEO

Justus Felix Wehmer, CFO

February 10, 2023

Agenda

01 3M 2022/23 at a Glance

02 Financial Performance

03 Focus Topics

04 Outlook

ZEISS

Page 2

Solid revenue growth with continued high order backlog in 3M 2022/23 Cost inflation and supply chain difficulties still in place

3M 2022/23

3M 2021/22

3M 2022/23

3M 2021/22

3M 2022/23

3M 2021/22

		Revenue
	€ 470.3 million	 FX-adj. revenue growth of +12.1%
	 Positive 3M revenue trend despite supply chain constraints and volatility of
	+14.6%
410.2	consumables in China
	 Strong order book at over € 600m - book to bill ratio for Q1 remains near 1.0
		 Growth in all regions led by Americas
		EBIT
	€ 60.3 million	 EBIT margin at 12.8% significantly lower yoy (PY 18.1%)
	 Gross profit improvement due to strong topline growth while input cost pressure remains high, gross
	-19.0%
	margin impacted by weaker consumables mix (impact of China lockdowns and decline in Korean
	74.4
	multifocal IOL business)
		 Higher OpEx mainly arising from strategic R&D investments and payroll cost increase
		 Adj. EBIT margin at 13.4% (PY 18.6%)
		EPS
	€ 0.57	 Hedging gain contributes to positive EPS trend
0.42	+34.5%

ZEISS

Page 3

Agenda

01 3M 2022/23 at a Glance

02 Financial Performance

03 Focus Topics

04 Outlook

ZEISS

Page 4

Ophthalmology

Good revenue conversion in difficult environment for consumable business

3M 2022/23

3M 2021/22

Revenue

€ 358.2 million		FX-adj. revenue growth of +12.7%
+15.2%		Major growth contribution from devices; consumables grew slower in a difficult environment
310.9		with surgical procedures in China and multifocal IOLs in South Korea facing headwinds

EBIT margin

3M 2022/23

3M 2021/22

10.1%	 EBIT margin decline of -6.5 pps primarily affected by:
− Weaker product mix due to slowdown in refractive procedures and multifocal
16.6%		IOLs amid high procurement cost
−	Increase in OpEx, particularly strategic R&D investment (Digital, Surgical

Ophthalmology, Regulatory Affairs)

Revenue Split

MCS

OPT	76.2%
of total revenue

ZEISS

Page 5